Outcome of adjuvant chemotherapy in elderly patients with early-stage, hormone receptor-positive, HER-2-negative breast cancer.
Sung Jun MaOluwadamilola T OladeruAnurag K SinghPublished in: The breast journal (2020)
The proportion of breast cancer cases among elderly (over 70 years old) patients is expected to rise from 24% to 35% by the next decade. However, elderly patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER-2)-negative, node-negative breast cancer were underrepresented in prior landmark prospective trials. Using a nationwide hospital cancer registry, our study of 12 004 elderly patients demonstrates that adjuvant chemotherapy was not associated with overall survival (hazards ratio [HR] 0.96, 95% confidence interval [CI] 0.77-1.20, P = .71). Given the toxicities associated with systemic treatment, cautious recommendation or the omission of chemotherapy may be considered in select elderly patients.
Keyphrases
- epidermal growth factor receptor
- early stage
- end stage renal disease
- endothelial cells
- tyrosine kinase
- ejection fraction
- chronic kidney disease
- newly diagnosed
- advanced non small cell lung cancer
- middle aged
- healthcare
- peritoneal dialysis
- lymph node
- community dwelling
- squamous cell carcinoma
- emergency department
- childhood cancer
- cross sectional
- neoadjuvant chemotherapy
- replacement therapy
- patient reported
- acute care